Genitourinary Active Clinical Trials

Numerous clinical trials are always active (ie, open and enrolling patients) in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults who have or are at risk of developing cancer. The buttons below depict the general research categories being investigated in ECOG-ACRIN clinical trials. To access information within a particular category, click on the relevant button. Upon clicking, the color of the button will change from grey to red, and a table will appear on screen. The table will display the study number, study description, lead investigator(s), accrual goal, and the date participating institutions started to open the trial. Please read the ECOG-ACRIN Disclaimer in its entirety before accessing this information.

Need More Information About a Particular Clinical Trial? Contact Us

To view educational materials, click on the links provided in the Educational Materials column. To send an email to the study chair, click on their name and a new email window will open.

Brain

Breast

Cancer Care Delivery Research

Cancer Control and Survivorship

Trials Currently Recruiting Participants - Genitourinary Cancer Committee

STUDY	DESCRIPTION	ECOG-ACRIN STUDY CHAIR (STATISTICIAN)	ACCRUAL GOAL	DATE ACTIVATED	EDUCATIONAL MATERIALS
EA8134 aka InPACT	International Penile Advanced Cancer Trial Sponsored by The Institute of Cancer Research (UK/EU) on behalf of the International Rare Cancers Initiative in Penile Cancer UK Group, and the National Cancer Institute (US) Coordinated in the US by the ECOG-ACRIN Cancer Research Group	Curtis A. Pettaway, MD, Chair (Yu-Hui Chen, MPH, MS)	400 internationally	09/08/2017 in the U.S.	EA8134 Resources
EA8143 aka PROSPER RCC	A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)	Mohamad E. Allaf, MD, Chair David F. McDermott, MD, Co-Chair (Maneka Puligandla, MS)	766	02/02/2017	EA8143 Resources
EA8153 aka CHAARTED2	Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel	Christos Kyriakopoulos, MD, Chair Glenn Liu, MD, Co-Chair (Yu-Hui Chen, MPH, MS)	210	02/08/2018	EA8153 Resources
EA8171	Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer	Clare M. Tempany, MD, Chair Rajan Gupta, MD, Co-Chair (Zheng Zhang)	852	10/10/2018	EA8171 Resources
EA8185	Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE)	Monika Joshi, MD, MRCP (Maneka Puligandla, MS)	114	08/25/2020	EA8185 Resources
EA8191	Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence	Neha Vapiwala, MD Steve Cho, MD, Co-Chair (Yu-Hui Chen, MS, MPH)	804	10/08/2020	EA8191 Resources

STUDY DESCRIPTION ECOG-ACRIN STUDY CHAIR
(STATISTICIAN) ACCRUAL
GOAL DATE
ACTIVATED EDUCATIONAL MATERIALS

EA8134 aka InPACT International Penile Advanced Cancer Trial

Sponsored by The Institute of Cancer Research (UK/EU) on behalf of the International Rare Cancers Initiative in Penile Cancer UK Group, and the National Cancer Institute (US)

Coordinated in the US by the ECOG-ACRIN Cancer Research Group Curtis A. Pettaway, MD, Chair
(Yu-Hui Chen, MPH, MS) 400
internationally 09/08/2017
in the U.S. EA8134 Resources

EA8143
aka
PROSPER RCC A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) Mohamad E. Allaf, MD, Chair
David F. McDermott, MD, Co-Chair
(Maneka Puligandla, MS) 766 02/02/2017 EA8143 Resources

EA8153 aka CHAARTED2 Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel Christos Kyriakopoulos, MD, Chair
Glenn Liu, MD, Co-Chair
(Yu-Hui Chen, MPH, MS) 210 02/08/2018 EA8153 Resources

EA8171 Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer Clare M. Tempany, MD, Chair
Rajan Gupta, MD, Co-Chair
(Zheng Zhang) 852 10/10/2018 EA8171 Resources

EA8185 Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage 3, Node Positive Bladder Cancer (INSPIRE) Monika Joshi, MD, MRCP
(Maneka Puligandla, MS) 114 08/25/2020 EA8185 Resources

EA8191 Phase III Study of PET-Directed Local or Systemic Therapy Intensification in Prostate Cancer Patients with Post-Prostatectomy Biochemical Recurrence Neha Vapiwala, MD
Steve Cho, MD, Co-Chair
(Yu-Hui Chen, MS, MPH) 804 10/08/2020 EA8191 Resources

Download